Literature DB >> 24300735

Design of small molecule epigenetic modulators.

Boobalan Pachaiyappan1, Patrick M Woster2.   

Abstract

The field of epigenetics has expanded rapidly to reveal multiple new targets for drug discovery. The functional elements of the epigenomic machinery can be categorized as writers, erasers and readers, and together these elements control cellular gene expression and homeostasis. It is increasingly clear that aberrations in the epigenome can underly a variety of diseases, and thus discovery of small molecules that modulate the epigenome in a specific manner is a viable approach to the discovery of new therapeutic agents. In this Digest, the components of epigenetic control of gene expression will be briefly summarized, and efforts to identify small molecules that modulate epigenetic processes will be described.
Copyright © 2013 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Acetyllysine; Epigenetic; Histone; Methylarginine; Methyllysine

Mesh:

Substances:

Year:  2013        PMID: 24300735      PMCID: PMC3879946          DOI: 10.1016/j.bmcl.2013.11.001

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  134 in total

Review 1.  Unsafe SETs: histone lysine methyltransferases and cancer.

Authors:  Robert Schneider; Andrew J Bannister; Tony Kouzarides
Journal:  Trends Biochem Sci       Date:  2002-08       Impact factor: 13.807

2.  Effects of a novel arginine methyltransferase inhibitor on T-helper cell cytokine production.

Authors:  Kevin Bonham; Saskia Hemmers; Yeon-Hee Lim; Dawn M Hill; M G Finn; Kerri A Mowen
Journal:  FEBS J       Date:  2010-03-22       Impact factor: 5.542

3.  Crystal structure of the nucleosome core particle at 2.8 A resolution.

Authors:  K Luger; A W Mäder; R K Richmond; D F Sargent; T J Richmond
Journal:  Nature       Date:  1997-09-18       Impact factor: 49.962

4.  Novel inhibitors for PRMT1 discovered by high-throughput screening using activity-based fluorescence polarization.

Authors:  Myles B C Dillon; Daniel A Bachovchin; Steven J Brown; M G Finn; Hugh Rosen; Benjamin F Cravatt; Kerri A Mowen
Journal:  ACS Chem Biol       Date:  2012-04-20       Impact factor: 5.100

5.  Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain.

Authors:  Qin Feng; Hengbin Wang; Huck Hui Ng; Hediye Erdjument-Bromage; Paul Tempst; Kevin Struhl; Yi Zhang
Journal:  Curr Biol       Date:  2002-06-25       Impact factor: 10.834

6.  Histone H3 lysine 4 methylation patterns in higher eukaryotic genes.

Authors:  Robert Schneider; Andrew J Bannister; Fiona A Myers; Alan W Thorne; Colyn Crane-Robinson; Tony Kouzarides
Journal:  Nat Cell Biol       Date:  2003-12-07       Impact factor: 28.824

7.  Vorinostat, a histone deacetylase inhibitor, suppresses dendritic cell function and ameliorates experimental autoimmune encephalomyelitis.

Authors:  Zhenzhen Ge; Yurong Da; Zhenyi Xue; Kai Zhang; Hao Zhuang; Meiyu Peng; Yan Li; Wen Li; Alain Simard; Junwei Hao; Zhi Yao; Rongxin Zhang
Journal:  Exp Neurol       Date:  2012-12-21       Impact factor: 5.330

Review 8.  EZH2, an epigenetic driver of prostate cancer.

Authors:  Yeqing Angela Yang; Jindan Yu
Journal:  Protein Cell       Date:  2013-04-30       Impact factor: 14.870

Review 9.  Histone deacetylases.

Authors:  Paul A Marks; Thomas Miller; Victoria M Richon
Journal:  Curr Opin Pharmacol       Date:  2003-08       Impact factor: 5.547

10.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.

Authors:  Laurens Kruidenier; Chun-wa Chung; Zhongjun Cheng; John Liddle; KaHing Che; Gerard Joberty; Marcus Bantscheff; Chas Bountra; Angela Bridges; Hawa Diallo; Dirk Eberhard; Sue Hutchinson; Emma Jones; Roy Katso; Melanie Leveridge; Palwinder K Mander; Julie Mosley; Cesar Ramirez-Molina; Paul Rowland; Christopher J Schofield; Robert J Sheppard; Julia E Smith; Catherine Swales; Robert Tanner; Pamela Thomas; Anthony Tumber; Gerard Drewes; Udo Oppermann; Dinshaw J Patel; Kevin Lee; David M Wilson
Journal:  Nature       Date:  2012-08-16       Impact factor: 49.962

View more
  6 in total

Review 1.  KDM1 class flavin-dependent protein lysine demethylases.

Authors:  Jonathan M Burg; Jennifer E Link; Brittany S Morgan; Frederick J Heller; Amanda E Hargrove; Dewey G McCafferty
Journal:  Biopolymers       Date:  2015-07       Impact factor: 2.505

2.  Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.

Authors:  Yukihiro Itoh; Hideyuki Sawada; Miki Suzuki; Toshifumi Tojo; Ryuzo Sasaki; Makoto Hasegawa; Tamio Mizukami; Takayoshi Suzuki
Journal:  ACS Med Chem Lett       Date:  2015-04-23       Impact factor: 4.345

3.  Inhibition of the histone demethylase KDM4B leads to activation of KDM1A, attenuates bacterial-induced pro-inflammatory cytokine release, and reduces osteoclastogenesis.

Authors:  Joy E Kirkpatrick; Keith L Kirkwood; Patrick M Woster
Journal:  Epigenetics       Date:  2018-08-07       Impact factor: 4.528

4.  Investigation of indolglyoxamide and indolacetamide analogues of polyamines as antimalarial and antitrypanosomal agents.

Authors:  Jiayi Wang; Marcel Kaiser; Brent R Copp
Journal:  Mar Drugs       Date:  2014-05-28       Impact factor: 5.118

5.  Effect of SMYD3 on biological behavior and H3K4 methylation in bladder cancer.

Authors:  Xiang Wu; Qingjiang Xu; Pingzhou Chen; Chenbo Yu; Liefu Ye; Chen Huang; Tao Li
Journal:  Cancer Manag Res       Date:  2019-09-02       Impact factor: 3.989

Review 6.  Synthesis of lysine methyltransferase inhibitors.

Authors:  Chunngai Hui; Tao Ye
Journal:  Front Chem       Date:  2015-07-23       Impact factor: 5.221

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.